TRICON8

TRICON8 is the translational research sub-study of the ICON8 trial. Its aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8 is a phase III randomised controlled trial designed to investigate the safety and efficacy of two dose-dense, dose-fractionated, weekly carboplatin-paclitaxel combination chemotherapy regimens for the treatment of newly diagnosed ovarian cancer compared to standard three-weekly carboplatin-paclitaxel. There is a growing body of evidence that using dose-fractionated paclitaxel in particular may have increased anti-tumour effects, and this is thought to be due to enhanced anti-angiogenic and pro-apoptotic effects.

Existing samples:

  • Malignant tumor of ovary (disorder)

Bespoke collection capabilities:

  • Malignant tumor of ovary (disorder)

Contact Information

Email:
mrcctu.icon8and8b@ucl.ac.uk
Address:

Cambridge Cancer Trials Centre
Cambridge Clinical Trials Unit - Cancer Theme
Cambridge University Hospitals NHS Foundation Trust
Box 279 (S4), Addenbrooke's Hospital, Hills Road
Cambridge
Cambridgeshire
CB2 0QQ
England

Last Updated: 22/05/2019


Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A
2021 N/A N/A N/A N/A N/A N/A
2022 N/A N/A N/A N/A N/A N/A